Orphan Drug Congress 2012

Fleming Europe following the development of orphan drugs
 
Because rare diseases affect only a tiny group of people, pursuing the development of treatments has traditionally not been attractive for pharma companies. However, there are currently lucrative benefits in place set by the regulatory bodies that reward R&D efforts for orphan drugs by ensuring less intense competition, faster and less expensive development, protocol assistance and lower marketing expenses.
 
In order to discuss major concerns, the newest solutions and challenges resulting from these tendencies, Fleming Europe has organized its 2nd Annual Orphan Drug Congress 2012. On 17 – 18 October the top-level pharmaceutical experts in orphan drug development, regulatory affairs & pricing will gather in sunny Barcelona to discuss this year's critical issues.
 
Segolene Ayme, Director of Research from INSERM will open the conference with the International Rare Disease Research Initiative. Topics such as successful development plans for orphan drugs including designation, clinical and regulatory challenges, and the use of patient registries for rare diseases will follow during the day.
 
Pricing, reimbursment and market access working strategies, importance of communication between pharma, patients & HTA bodies, the use of open innovation in rare diseases and patient & patient organization perspectives will be covered during the second day of the event.
 
Focused interactive discussions integrated between individual presentation blocks will provide enough space and a unique opportunity to exchange ideas with industry peers and get the answers from our speakers.
 
Since existing rare diseases are spreading and new ones continue to emerge, it is more vital to attract the interest of pharmaceutical companies to rise to the challenge and incorporate orphan drugs into their pipelines.
 
About Fleming Europe

Established in Slovakia, Fleming Europe represents a Pan-European B2B networking channel for specialists to collect & share knowledge. Since 2004, the company has been encouraging decision makers in sharing their experiences through market leading conferences, trainings and webinars. The annual audience of 10,000 Banking, Defense, Energy, Oil & Gas, Pharma, Telco and Transport peers benefit from insights on industry trends when applying them to their own business practices.
For more information visit http://www.flemingeurope.com/

Recent Issues